Q-omics provides the consensus-scored METTL27 profile across patient tissues and cancer cell-line models. METTL27 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, METTL27 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, METTL27 RNA expression shows 14,576 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, KIRP, and LSCC as cancer lineages where METTL27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL27 survival associations across molecular data types. METTL27 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL27 RNA expression–survival associations across cancer types. High METTL27 expression shows unfavorable associations in COAD, LGG and CHOL, but favorable associations in KIRP, KIRC and UVM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for METTL27 RNA expression.
This table summarizes METTL27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for METTL27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL27 shows higher tumor expression in KIRP, KIRC, COAD, LIHC, STAD and ESCA. The KIRP box plot shows higher METTL27 RNA expression in tumor versus normal tissue (log2 FC = +1.901, t-test p < 0.001).
This table shows molecular features associated with METTL27 in patient tissues and cancer cell lines. In patient samples, METTL27 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
